SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Kosan BioSciences -- KOSN
An SI Board Since May 2001
Posts SubjectMarks Bans Symbol
933 40 0 KOSN
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
433Mol Cancer Ther. 2004 May;3(5):551-66. Simultaneous inhibition of hsp 90 and scaram(o)uche-5/15/2004
432ever informative..Kosan Reports First Quarter Financial Results Tuesday April 2mopgcw-4/27/2004
43117-Allylamino-17-Demethoxygeldanamycin (17-AAG) abrogates the G2/M cell cycle chscaram(o)uche-4/21/2004
430finance.yahoo.comscaram(o)uche-4/20/2004
429Oncogene. 2004 Apr 12 [Epub ahead of print] Requirement of Hsp90 activity for scaram(o)uche-4/13/2004
428Kosan Receives National Cancer Institute Grant to Discover Second-Generation Hspscaram(o)uche-4/13/2004
427nah.scaram(o)uche-4/1/2004
426Could you be developing a new 'passion' ? <g> (http://www.siliconigel bates-4/1/2004
425I have long used phase II awards as a strong upside indicator, and look forward scaram(o)uche-4/1/2004
424Kosan Receives NCI Grant to Develop Production Method for Analogs of Promising Anigel bates-4/1/2004
423Kosan's AACR Data Provides Rationale for KOS-862 (Epothilone D) Combination mopgcw-3/31/2004
422"B" and grain of salt..... Gynecol Oncol. 2004 Apr;93(1):19-26. Tuscaram(o)uche-3/30/2004
421Kosan's AACR Data Indicates Strong Synergy of Hsp90 Inhibitor, 17-AAG, in PrIRWIN JAMES FRANKEL-3/29/2004
420Thanks for the correction. Meanwhile, this teaser showed up today without text:tuck-3/24/2004
419Dr Kenneth Anderson. Actually he is not affiliated to Millennium. He is a leadiIcebrg-3/22/2004
418Dr. Anderson, of Millenium, will be discussing the combination of 17 AAG and veltuck-3/22/2004
417Dr. Anderson, of Millenium, will be discussing the combination of 17 AAG and veltuck-3/22/2004
416Int J Cancer. 2004 May 1;109(5):643-52. Geldanamycin, an inhibitor of the chascaram(o)uche-3/6/2004
415Kosan Initiates First KOS-862 Phase Ib Chemotherapy Combination Trial Thursday Mmopgcw-3/4/2004
414The Penn team keeps adding cytotoxins to 17AAG and finds synergism in some linestuck-2/29/2004
413And a PLS primer which explains some of this stuff (a little) more simply... plnigel bates-2/27/2004
412Engineered Biosynthesis of Regioselectively Modified Aromatic Polyketides Using nigel bates-2/27/2004
411Kosan Reports Fourth Quarter and Year End Financial Results and Provides 2004 Fimopgcw-2/26/2004
410Cancer Res. 2004 Feb 15;64(4):1460-7. Herceptin-geldanamycin immunoconjugatesscaram(o)uche-2/21/2004
409Tuck--Any thoughts on Kosan's stock price drop? It's now well below its JOEBT1-2/19/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News